Genome-edited green perilla offers a glimpse of crop redesign without foreign DNA

On 16 July 2026, a team at Hiroshima University published the most detailed account yet of a perilla plant that looks nothing like the crop Japanese and Korean kitchens have used for centuries. By disabling one enzyme gene, the researchers produced a green-leafed plant whose chemistry has been quietly rearranged: the molecular family that gives shiso its red-purple colour has been redirected into compounds associated with antioxidant and anti-inflammatory activity. The result is a perilla that resembles a different species altogether, built without inserting any foreign DNA.

The study matters less for any single dish it might season than for what it says about the widening toolkit available to plant breeders. Genome editing of this kind does not pull genes from another organism; it edits the plant's own instructions. That distinction has become a fault line in global food regulation, with Japan and several other Asian jurisdictions treating such crops differently from transgenic GMOs. Hiroshima's perilla sits squarely on the permissive side of that line, and the researchers are explicit that they want the work read as a demonstration of what precision breeding can deliver.

A single enzyme, redirected

Perilla, the mint-family herb used across East Asia in sushi, kimchi, pickled plums and a widening range of nutraceuticals, comes in two main forms. Red perilla owes its colour to a class of pigments called anthocyanins, the same family that colours blueberries and red cabbage. Green perilla, called ao-shiso in Japan, lacks those pigments because the biochemical pathway that would produce them is partially shut down.

The Hiroshima team, working in the laboratory of biofunctional science, targeted the gene for one enzyme in that pathway. According to the project's published summary, disabling the gene produced plants that outwardly resembled green perilla but, more surprisingly, accumulated higher measured levels of rosmarinic acid and related phenolic compounds than either parent type. Rosmarinic acid is the molecule food chemists tend to circle when they talk about perilla's putative health benefits: antioxidant, anti-inflammatory, studied in cell and animal models for effects on allergic response and lipid metabolism.

In other words, the colour gene and the health-promoting metabolite pathway turned out to be biochemically entangled. Closing one valve rerouted flux into the other. The team has not claimed a functional food breakthrough; the framing is careful, the language measured. What they have shown is that a single edit can reshape a plant's secondary metabolism in directions that breeding selection could not easily reach.

Why the regulatory shape matters

The technique used is a form of targeted mutagenesis: a genome editor is delivered into plant cells, where it makes a small, precise change to an existing gene. No foreign gene is inserted. Under Japanese regulation, and under the looser frameworks in several other Asian countries, such crops have so far faced a less onerous path to field trials and commercialisation than transgenic varieties carrying, for instance, bacterial genes for pest resistance.

The European Union moved in the early 2020s to relax its earlier strict position on plants produced by such techniques, but the regulatory picture across the continent remains uneven. The United States, under successive USDA rulings, has generally treated genome-edited plants without introduced DNA as outside the older GMO oversight regime. The Hiroshima work is therefore not just a botanical result; it is also a quiet argument for the regulatory lane its authors are working in.

The point is worth stating because it determines who can commercialise what. A breeding line that emerges from genome editing can, in principle, reach farmers and food companies faster and cheaper than a transgenic counterpart. For a country like Japan, with a heritage crop culture and a strong nutraceutical industry, that distinction is commercially significant.

What the sources do, and do not, claim

The public summary of the work, distributed via Phys.org, is short on quantitative detail. It identifies the targeted enzyme, describes the resulting phenotype, and reports an increase in phenolic content. It does not publish the magnitude of that increase, the specific analytical methods used, or whether the edited perilla has been grown beyond laboratory conditions. It does not yet report field-trial data, food-safety assessment, or any commercial partner.

That gap is normal at this stage of disclosure. Genome-editing studies in plants typically appear first as laboratory characterisations, with agronomic and compositional follow-up published later. Readers should treat the headline claim about enriched health-promoting molecules as directionally supported rather than numerically settled.

A widening Asian pipeline

Perilla joins a small but growing list of crops whose chemistry has been rewritten through targeted editing of native genes. Japanese research groups have published similar work on tomatoes bred for higher gamma-aminobutyric acid content, on rice engineered for reduced allergenicity, and on soybeans with altered fatty-acid profiles. South Korean labs have edited capsicum for colour and metabolite content. Chinese breeding programmes have used related techniques on wheat and maize. None of these efforts is a wholesale redesign; each adjusts a small number of well-characterised genes and observes how the plant's metabolism responds.

The structural pattern is consistent. Where industrial-scale transgenic commodity crops have stalled under regulatory and consumer resistance, particularly in Europe and parts of East Asia, the centre of gravity has shifted to crops with regional or culinary significance, edited with techniques that do not introduce foreign DNA. The commercial logic is straightforward: a genome-edited perilla or tomato with a documented change in a metabolite of interest can be marketed to food and cosmetics manufacturers faster than a transgenic staple ever could.

For now, Hiroshima's green perilla is a laboratory plant. Whether it becomes a field crop will depend on regulatory clearance in target markets, on the cost of seed production, and on whether nutraceutical buyers actually pay a premium for a verified phenolic content. The science is the easier part. The harder part, as ever, is moving from a published edit to a commercial ingredient.

Monexus framed this as a regulatory-and-metabolism story, not a GMO referendum. The technical distinction between editing native genes and inserting foreign DNA is doing real work in Asian food policy, and the perilla result sits cleanly inside that distinction.